Skip to main content
. 2022 Mar 18;5(11):e1613. doi: 10.1002/cnr2.1613

FIGURE 3.

FIGURE 3

Overall survival and progression‐free survival outcomes in the sorafenib and lenvatinib group. (A) Kaplan–Meier estimates of overall survival in the sorafenib by mG8 scores. (B) Kaplan–Meier estimates of progression‐free survival in the sorafenib by mG8 scores. (C) Kaplan–Meier estimates of overall survival in the lenvatinib by mG8 scores. (D) Kaplan–Meier estimates of progression‐free survival in the lenvatinib by mG8 scores